Table 3.
Proportion of cancer subtypes for all deaths among individuals exposed to proton pump inhibitors (PPI), H2-receptor antagonists (H2RA), and the corresponding background population for 2006–2013
| PPI (N = 27,994) | H2RA (N = 560) | Background population (2006–2013) |
||||
|---|---|---|---|---|---|---|
| Men | Women | Men | Women | Men | Women | |
| N (%) | N (%) | N (%) | N (%) | N (%) | N (%) | |
| Total | 13,552 (100) | 14,442 (100) | 267 (100) | 293 (100) | 85,117 (100) | 78,534 (100) |
| Non-gastrointestinal cancer deaths | 8283 (61.1) | 9393 (65.0) | 201 (75.2) | 200 (68.2) | 59,021 (69.3) | 54,009 (68.8) |
| Lung | 2368 (17.5) | 2586 (17.9) | 73 (27.3) | 68 (23.2) | 13,998 (16.4) | 12,622 (16.1) |
| Prostate | 1853 (13.7) | n.a | 32 (11.9) | n.a | 18,140 (21.3) | n.a |
| Breast | 4 (0.0) | 1181 (8.2) | 0 (0.0) | 23 (7.8) | 88 (0.1) | 10,851 (13.8) |
| Other | 4058 (29.9) | 5627 (38.9) | 92 (34.4) | 106 (36.2) | 26,795 (31.4) | 30,536 (38.9) |
| Gastrointestinal cancer deaths | 5273 (38.9) | 5057 (35.0) | 66 (24.7) | 93 (31.7) | 25,727 (30.2) | 24,186 (30.8) |
| Colorectal | 1590 (11.7) | 1783 (12.3) | 22 (8.2) | 33 (11.2) | 9962 (11.7) | 9661 (12.3) |
| Pancreas | 1165 (8.5) | 1422 (9.9) | 21 (7.8) | 27 (9.2) | 5619 (6.6) | 6337 (8.1) |
| Liver, gallbladder and bile ducts | 911 (6.7) | 813 (5.6) | 12 (4.5) | 20 (6.8) | 3813 (4.5) | 3976 (5.1) |
| Stomach | 765 (5.6) | 547 (3.8) | 5 (1.9) | 5 (1.7) | 2993 (3.5) | 2045 (2.6) |
| Oesophagus | 623 (4.6) | 218 (1.5) | 3 (1.1) | 0 (0.0) | 2237 (2.6) | 828 (1.1) |
| Other gastrointestinal | 219 (1.6) | 274 (1.9) | 3 (1.1) | 8 (2.7) | 1103 (1.3) | 1341 (1.7) |